Chronic Granulomatous Disease with the McLeod Phenotype: a French National Retrospective Case Series
Background X-linked chronic granulomatous disease (CGD) is a primary immunodeficiency caused by mutations in the CYBB gene (located on Xp21.1). Patients with large deletions on chromosome Xp21.1 can present with the McLeod phenotype and also Duchenne muscular dystrophy or retinitis pigmentosa. The objective of the present study was to describe a series of French patients with CGD and the McLeod phenotype. Methods We retrospectively collected data from the medical records of 8 patients with CGD and the McLeod phenotype registered at the French National Reference Center for blood types. Results The median age at diagnosis of CGD was 1.2 years, the median age at diagnosis of the McLeod phenotype was 4.5 years, and the median length of follow-up was 15.2 years. Four patients displayed allo-immunization, with anti-KEL20 and anti-XK1 (formerly known as anti-KL) antibodies. Five of the 6 patients with available blood smears had acanthocytosis. Neuropsychiatric, muscle-related, and ocular manifestations were present in 4, 2, and 1 of the patients, respectively. Three of the 4 patients having undergone allogeneic hematopoietic stem cell transplantation (HSCT) are alive. Overall, 5 patients are alive, and 3 are alive and well. Conclusion This is the largest yet descriptive study of a series of patients with X-linked CGD and the McLeod phenotype. Although this disease combination is rare, the timely, accurate diagnosis of the McLeod phenotype is critical because of the serious post-transfusion complications. However, HSCT can be considered in these patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of clinical immunology - 40(2020), 5 vom: 19. Juni, Seite 752-762 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lhomme, Faustine [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| doi: |
10.1007/s10875-020-00791-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR040380572 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040380572 | ||
| 003 | DE-627 | ||
| 005 | 20230519193258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10875-020-00791-w |2 doi | |
| 035 | |a (DE-627)SPR040380572 | ||
| 035 | |a (SPR)s10875-020-00791-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Lhomme, Faustine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic Granulomatous Disease with the McLeod Phenotype: a French National Retrospective Case Series |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background X-linked chronic granulomatous disease (CGD) is a primary immunodeficiency caused by mutations in the CYBB gene (located on Xp21.1). Patients with large deletions on chromosome Xp21.1 can present with the McLeod phenotype and also Duchenne muscular dystrophy or retinitis pigmentosa. The objective of the present study was to describe a series of French patients with CGD and the McLeod phenotype. Methods We retrospectively collected data from the medical records of 8 patients with CGD and the McLeod phenotype registered at the French National Reference Center for blood types. Results The median age at diagnosis of CGD was 1.2 years, the median age at diagnosis of the McLeod phenotype was 4.5 years, and the median length of follow-up was 15.2 years. Four patients displayed allo-immunization, with anti-KEL20 and anti-XK1 (formerly known as anti-KL) antibodies. Five of the 6 patients with available blood smears had acanthocytosis. Neuropsychiatric, muscle-related, and ocular manifestations were present in 4, 2, and 1 of the patients, respectively. Three of the 4 patients having undergone allogeneic hematopoietic stem cell transplantation (HSCT) are alive. Overall, 5 patients are alive, and 3 are alive and well. Conclusion This is the largest yet descriptive study of a series of patients with X-linked CGD and the McLeod phenotype. Although this disease combination is rare, the timely, accurate diagnosis of the McLeod phenotype is critical because of the serious post-transfusion complications. However, HSCT can be considered in these patients. | ||
| 650 | 4 | |a McLeod phenotype |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a chronic granulomatous disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a contiguous X-chromosome gene deletion syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a case series |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a primary immunodeficiency |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a acanthocytosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a allogeneic hematopoietic stem cell transplantation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a epidemiology |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Peyrard, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Babinet, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Abou-Chahla, Wadih |e verfasserin |4 aut | |
| 700 | 1 | |a Durieu, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Moshous, Despina |e verfasserin |4 aut | |
| 700 | 1 | |a Neven, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Rohrlich, Pierre-Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Albinni, Souha |e verfasserin |4 aut | |
| 700 | 1 | |a Amiranoff, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Dumont, Marie-Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Lortholary, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Héritier, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Marguet, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Suarez, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Blanche, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Hermine, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Mahlaoui, Nizar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1981 |g 40(2020), 5 vom: 19. Juni, Seite 752-762 |w (DE-627)SPR014233401 |w (DE-600)2016755-6 |x 1573-2592 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:5 |g day:19 |g month:06 |g pages:752-762 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10875-020-00791-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |q ASE |
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 5 |b 19 |c 06 |h 752-762 | ||